← Eichor
Condition: Glomerulonephritis Minimal Lesion Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Glomerulonephritis Minimal Lesion

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Non-invasive Diagnosis of Idiopathic Nephrotic Syndromes
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06820866Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07010250NEPTUNE Match Study
NA · 16 location(s) · University of Michigan · NCT04571658Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Phase N/A · 1 location(s) · University of Michigan · NCT05505500Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome
Phase 3 · 18 location(s) · Shoichi Maruyama MD PhD · NCT05914155The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
Phase N/A · 12 location(s) · Prof. Dr. Paul Brinkkoetter · NCT03949972Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Phase 2 · 47 location(s) · Travere Therapeutics, Inc. · NCT05003986A National Prospective Cohort of Patients With Idiopathic Nephrotic Syndrome Beginning in Childhood.
Phase N/A · 48 location(s) · University Hospital, Limoges · NCT04207580Study of WAL0921 in Patients With Glomerular Kidney Diseases
Phase 2 · 50 location(s) · Walden Biosciences · NCT06466135INSIGHT (Insight Into Nephrotic Syndrome)
Phase N/A · 4 location(s) · The Hospital for Sick Children · NCT01605266Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
Phase N/A · 1 location(s) · Mario Negri Institute for Pharmacological Research · NCT06334692A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)
Phase 2 · 6 location(s) · Medical University Innsbruck · NCT07710157A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
Phase 2/Phase 3 · 1 location(s) · Bio-Thera Solutions · NCT07499700Nephrotic Syndrome Study Network
Phase N/A · 44 location(s) · University of Michigan · NCT01209000China Kidney Patient Trials Network
Phase N/A · 1 location(s) · George (Beijing) Clinical Research Co. Ltd. · NCT05036850A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
NA · 2 location(s) · Northwell Health · NCT05583942Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinur
Phase 2 · 2 location(s) · Everest Medicines (China) Co.,Ltd. · NCT07614477SLIT ABS: Study on Patients With Autoimmune Podocytopathy
NA · 14 location(s) · Meyer Children's Hospital IRCCS · NCT07516964A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Ye
Phase 2 · 71 location(s) · Sanofi · NCT06500702INS, B Cells and Microbiota
Phase N/A · 2 location(s) · Nantes University Hospital · NCT04924712National Registry of Rare Kidney Diseases
Phase N/A · 1 location(s) · UK Kidney Association · NCT06065852taVNS for FRNS in Children
NA · 2 location(s) · Northwell Health · NCT05588063KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Phase N/A · 6 location(s) · Seoul National University Hospital · NCT03929887Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Phase N/A · 1 location(s) · University of Michigan · NCT05650619
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.